Processa Pharmaceuticals Inc’s recent filing unveils that its Director Yorke Justin W acquired Company’s shares for reported $9889.0 on Jan 27 ’25. In the deal valued at $0.80 per share,12,400 shares were bought. As a result of this transaction, Yorke Justin W now holds 12,400 shares worth roughly $3224.0.
Then, Ng George K bought 87,200 shares, generating $69,542 in total proceeds. Upon buying the shares at $0.80, the Chief Executive Officer now owns 87,200 shares.
Before that, Young David bought 124,500 shares. Processa Pharmaceuticals Inc shares valued at $99,289 were divested by the Pres. Research & Development at a price of $0.80 per share. As a result of the transaction, Young David now holds 205,405 shares, worth roughly $53405.3.
H.C. Wainwright initiated its Processa Pharmaceuticals Inc [PCSA] rating to a Buy in a research note published on April 25, 2024; the price target was $8.
Price Performance Review of PCSA
On Friday, Processa Pharmaceuticals Inc [NASDAQ:PCSA] saw its stock fall -24.92% to $0.26. Over the last five days, the stock has lost -14.01%. Processa Pharmaceuticals Inc shares have fallen nearly -70.75% since the year began. Nevertheless, the stocks have fallen -85.64% over the past one year. While a 52-week high of $3.10 was reached on 01/06/25, a 52-week low of $0.15 was recorded on 04/17/25.
Levels Of Support And Resistance For PCSA Stock
The 24-hour chart illustrates a support level at 0.2393, which if violated will result in even more drops to 0.2202. On the upside, there is a resistance level at 0.2888. A further resistance level may holdings at 0.3192.
How much short interest is there in Processa Pharmaceuticals Inc?
A steep rise in short interest was recorded in Processa Pharmaceuticals Inc stocks on 2025-05-30, growing by 0.68 million shares to a total of 0.75 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-30 was 70227.0 shares. There was a rise of 90.66%, which implies that there is a positive sentiment for the stock.
